Stock analysts at HC Wainwright started coverage on shares of Mersana Therapeutics (NASDAQ:MRSN) in a report issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating on the stock.
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research raised Mersana Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. ValuEngine raised Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $23.67.
Mersana Therapeutics (NASDAQ:MRSN) opened at $15.36 on Thursday. Mersana Therapeutics has a one year low of $12.45 and a one year high of $21.01.
TRADEMARK VIOLATION WARNING: “Mersana Therapeutics (MRSN) Now Covered by HC Wainwright” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/15/hc-wainwright-initiates-coverage-on-mersana-therapeutics-mrsn.html.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.